Skip to content
Screener

Operating Income at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.25B+8.3%
Incyte logo
IncyteINCY
$697.9M+31.6%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$11.89M-7.0%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$110.92M-59.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$75M+30.6%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$2.41M+614%

Other financials

Income statement

See full
Revenue$44.7M+259%
Gross profit$41.7M+288%
Net income-$100.7M+10.1%
EPS (diluted)-$1.69+12.4%

Balance sheet

See full
Cash & equivalents$99.6M+23.2%
Total debt$31.2M-36.1%
Total equity$1.0B-25.1%
Total assets$1.1B-24.7%

Cash flow

See full
Operating cash flow-$57.3M+25.7%
CapEx$1.2M+38.5%
Free cash flow-$58.5M+25.0%

Valuation

See full
Market cap$1.91B-13.0%
Enterprise value$1.84B-14.8%
P/S19.4×-34.2×

Profitability

See full
Gross margin92%+3.8pp
Operating margin-466.8%-173pp
Net margin-418.2%
FCF margin-371.4%-143pp

Returns & leverage

See full
Return on equity-34.3%
Debt / equity0.0×
Current ratio10.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 9:56 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001439222-26-000118
(In thousands, except share and per share data)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development100,75491,940181,902164,683
Selling, general and administrative51,54745,86999,85187,396
Total operating expenses155,297139,511286,068254,866
Loss from operations(110,552)(127,056)(220,577)(233,685)
Interest income, net9,73014,51320,52530,600
Other income, net1195232381,776
Net loss$(100,703)$(112,020)$(199,814)$(201,309)
Net loss per share - basic and diluted$(1.69)$(1.93)$(3.38)$(3.49)

Item 1. Financial Statements (Unaudited)

FAQ

What is Agios Pharmaceuticals's operating income?
Agios Pharmaceuticals (AGIO) reported operating income of -$110.55M in Q2 2026.
How has Agios Pharmaceuticals's operating income changed year-over-year?
Agios Pharmaceuticals's operating income increased by 13.0% year-over-year, from -$127.06M to -$110.55M.
What is the long-term trend for Agios Pharmaceuticals's operating income?
Over 4 years (2021 to 2025), Agios Pharmaceuticals's operating income has grown at a 5.7% compound annual growth rate (CAGR), from -$378.42M to -$472.13M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Agios Pharmaceuticals's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude